WuXi AppTec Opens First cGMP Biologics Facility in China, Hosts Global Monoclonal Antibody Summit
Oct 13, 2012
WuXi AppTec recently reached another milestone. The company hosted an inaugural Global Monoclonal Antibody Summit in conjunction with the startup of its cGMP biologics manufacturing facility in Wuxi on October 10-12, 2012.
Attending the opening ceremony were former vice chairman of Chinese People's Political Consultative Conference (CPPCC), Mr. Zhang Huaixi; officials from State Food and Drug Administration (SFDA) and the National Development and Reform Commission (NDRC); the assistant of Jiangsu governor, Mr. Xu Nanping; mayor of Wuxi, Mr. Zhu Kejiang and other government officials. They pointed out that the biotech industry is strategically important in China’s 12th 5-year plan; and the Global Monoclonal Antibody Summit held by WuXi just fit the trend and provided an ideal platform for international academic exchanges. The officials congratulated WuXi’s progress and wished the company achieve greater success in future.
Dr. Ge Li, Chairman and CEO of WuXi AppTec, expressed his gratitude for the long term support from government, clients and partners and reaffirmed company’s commitment to providing world-class biologics services for its clients. He hoped that the constant communication and exchanging of ideas among scientists, researchers and entrepreneurs at the WuXi Summit could cultivate rich soil and inspire more creative ideas for China’s new drug R&D.
WuXi AppTec has invested substantially in building its capabilities and capacity in biologics in the past few years. The current startup of its biologics manufacturing facility in Wuxi, the first in China to meet GMP standards of the United States, the European Union and China, marked another milestone for the company. This facility also is the first one globally to utilize 100% disposable equipment for biologics drug substance manufacturing.
WuXi AppTec recently announced three deals in biologics: a collaboration with Open Monoclonal Technology to use OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats, to develop novel human antibodies for global clients; a contract with TaiMed Biologics to produce the HIV compound ibalizumab for global phase II and III clinical trials; and a joint venture agreement with MedImmune, the global biologics arm of AstraZeneca, to develop MEDI5117, an IL-6 inhibitor for rheumatoid arthritis and autoimmune disorders in China.
Dr. Martin Mackay, President of R&D at AstraZeneca stressed at the opening ceremony that the joint venture with WuXi would benefit both companies and he believed it was the two company’s mutual ambition to greatly increase the number of people who ultimately benefit from the new medicines.
A broad spectrum of topics relating to therapeutic antibodies was discussed at the Global Monoclonal Antibody Summit. Dr. David Ho, AIDS research pioneer, the key inventor of HIV cocktail treatment, described the anti-CD4 antibody ibalizumab in the treatment and prevention of HIV infection. The summit also included discussions of such new technologies as bi-specific antibodies and antibody-drug conjugates. A panel on The Future of the Chinese Mab Industry discussed the opportunities and challenges facing Chinese biopharmaceutical companies in the rapidly growing mab segment, which is strongly supported and funded by both governments and private industry.
Let’s congratulate the startup of cGMP biologics manufacturing facility in Wuxi and the success of the first Global Monoclonal Antibody Summit. Wish WuXi continued success in future!